Healthcare Providers and Services
Company Overview of InVitae Corporation
InVitae Corporation, a genetic information company, provides genetic diagnostics for various hereditary disorders. The company provides gene sequencing and deletion/duplication analysis for disorders in various medical specialties that include cardiology, such as long and short QT syndrome, Brugada syndrome, and hypertrophic cardiomyopathy; hereditary cancers, including breast, ovarian, and endometrial cancers, as well as colon and pancreatic cancers; pediatric genetics; neurology; and hematology. It also offers tools, such as Family History Tool that enables users to digitally build, modify, share, and save patient pedigrees, as well as assess their risks and decide on the appropriate genet...
458 Brannan Street
San Francisco, CA 94107
Founded in 2012
Key Executives for InVitae Corporation
Compensation as of Fiscal Year 2014.
InVitae Corporation Key Developments
Invitae Corporation and Nanopharmacia Announce Partnership to Make Reliable, Fast and Affordable Hereditary Cancer Genetic Testing Broadly Available in Mexico
Jul 30 14
Invitae Corporation and Nanopharmacia announced an exclusive partnership to make Invitae's genetic tests for the management of hereditary cancers broadly available throughout Mexico. In addition, the partnership includes access on a non-exclusive basis in Costa Rica and Panama. Nanopharmacia will offer Invitae's hereditary cancer panels and BRCA1/BRCA2 offering to a wide network of onco-geneticists and medical and surgical oncologists. Invitae's oncology offering includes: Single gene BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis; High-risk hereditary breast cancer panel (6 genes); Women's hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer); Hereditary cancer syndromes panel (29 genes); Hereditary Pancreatic Cancer Panel (17 genes); Additional hereditary cancer panels are available, including testing for Lynch Syndrome and colon cancers. The partnership includes access for advanced next generation genetic testing in Mexico through a network of approximately 800 oncology professionals in Mexico, as well as in Costa Rica and Panama.
InVitae Corporation Offers Multi-Gene Testing for Hereditary Pancreatic Cancer
Jun 12 14
Invitae Corporation announced that it now offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast and affordable option for their cancer patients and their families. With results typically available within three weeks, this panel includes an analysis of 17 genes and currently is the most comprehensive panel available. The test is available globally and at a contracted price of $1,500 in the United States. The new Invitae Hereditary Pancreatic Cancer Panel covers the genetic associations most commonly linked to an increased risk of pancreatic cancer and includes the following genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PALLD, PMS2, STK11, TP53 and VHL. In addition, Invitae offers hereditary pancreatitis genes CFTR and SPINK1, which some providers choose when assessing a patient for hereditary pancreatic cancer. These genes can be included in an Invitae requisition at no additional charge. Additional hereditary cancer panels are available, including testing for BRCA1 and BRCA2, Lynch Syndrome and other colon cancers, and a 29-gene hereditary cancer syndromes panel. In addition to covering more genes than tests available from other providers, Invitae's newest cancer panel provides clinicians and patients with answers more rapidly, at a lower cost.
InVitae Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 05:00 PM
Jan 10 14
InVitae Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 05:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Sean George PhD, President.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 13, 2014